PA
AIMT

Perceptive Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Perceptive Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,448
Closed -$70K – 222
2016
Q2 		$70K Buy
+6,448
New +$87.6K ﹤0.01% 156

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Perceptive Advisors's AIMT Position: Q3 2016 in Review

Perceptive Advisors sold out of Aimmune Therapeutics (AIMT) in Q3 2016, closing a stake of 6,448 shares — an estimated $70K sold.

Perceptive Advisors first reported a position in AIMT in Q2 2016 and held it in 1 quarter. The position peaked at $70K in Q2 2016. 74 funds tracked by Wall St. Rank hold AIMT as of Q3 2016.

  • Perceptive Advisors reported no remaining Aimmune Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Perceptive Advisors sold 6,448 Aimmune Therapeutics shares in Q3 2016, an estimated $70K.
  • Perceptive Advisors first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 1 quarter.
  • Perceptive Advisors's Aimmune Therapeutics position peaked at $70K in Q2 2016.
  • 74 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2016.

Based on Perceptive Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.